Portfolio company
Alentar
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops therapeutic agents to reverse goblet cell hyperplasia for patients with cystic fibrosis and other pulmonary conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Enterprise Therapeutics
This biopharmaceutical company develops novel muco-regulatory therapies for patients with respiratory diseases including cystic fibrosis, asthma and chronic obstructive pulmonary disease.
Kither Biotech
This company develops inhaled therapies for patients with respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis.
Attenua
This company develops small-molecule medicines for patients suffering from chronic respiratory disorders, particularly chronic cough.
AirNexis Therapeutics
This company develops inhaled small molecule medicines to treat chronic obstructive pulmonary disease for patients with respiratory conditions.
Aer Therapeutics
This biopharmaceutical company develops inhaled mucolytic treatments for patients with muco-obstructive lung diseases, including chronic obstructive pulmonary disease and asthma.
Gossamer Bio
This biopharmaceutical company develops inhaled therapies for patients suffering from pulmonary arterial hypertension and interstitial lung disease.
Altesa BioSciences
This company develops antiviral medicines for patients with chronic lung diseases such as COPD and asthma to prevent respiratory infections and illness flare-ups.
AirNexis
This clinical-stage biotechnology company develops inhaled therapies for patients with chronic obstructive pulmonary disease and other respiratory conditions.